Single Ascending Oral Doses of SY-008 in Healthy Subjects

NCT ID: NCT03462589

Last Updated: 2019-10-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 54 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-08-02
• Study Completion Date: 2018-12-30

Brief Summary

This is a phase Ⅰ，single-center, randomized, double-blinded, placebo-controlled, single ascending dose trial of SY-008 in healthy subjects.

Detailed Description

This is a randomized, double-blind, placebo-controlled, dosed tolerability, pharmacokinetic / pharmacodynamic study of a single oral SY-008 capsule for Chinese healthy subjects. Plan to screening total of 54 healthy subjects ， dividing them into 6 dose groups.

Conditions

Diabetes

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SY-008 dose 1

A single dose of SY-008 (2\~30mg) taken orally.

Group Type: EXPERIMENTAL

SY-008

Intervention Type: DRUG

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

SY-008 dose 2

A single dose of SY-008 (2\~30mg) taken orally.

Group Type: EXPERIMENTAL

SY-008

Intervention Type: DRUG

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

SY-008 dose 3

A single dose of SY-008 (2\~30mg) taken orally.

Group Type: EXPERIMENTAL

SY-008

Intervention Type: DRUG

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

SY-008 dose 4

A single dose of SY-008 (2\~30mg) taken orally.

Group Type: EXPERIMENTAL

SY-008

Intervention Type: DRUG

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

SY-008 dose 5

A single dose of SY-008 (2\~30mg) taken orally.

Group Type: EXPERIMENTAL

SY-008

Intervention Type: DRUG

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

SY-008 matching placebo

from 6mg to 30mg

Group Type: PLACEBO_COMPARATOR

SY-008

Intervention Type: DRUG

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Interventions

SY-008

The study will be initiated in healthy subjects at a 2-mg dose that is expected to have minimal pharmacologic effect. Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 6, 12, 18, 24, 30mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Gender: Male and female, gender balance.

2. Age: 18-65 years old (including the boundary values).

3. Weight ≥50kg and 19kg / m2 ≤ BMI ≤ 28kg / m2 [BMI = body weight (kg) / height 2 (m2).

4. fasting plasm glucose (FPG): 3.9-6.1mmol / L (excluding the boundary values).

5. glycosylated hemoglobin (HbA1c) <6.5%.

6. healthy subjects determined by medical history, physical examination, electrocardiogram and laboratory tests. Test results within the normal range for the population or investigator site, or with abnormalities deemed clinically insignificant by the investigator.

7. have venous access sufficient to allow blood sampling as per the protocol.

8. have given written informed consent approved by sponsors and the ethical review board governing the site.

9. are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

Exclusion Criteria

1. are investigator site personnel directly affiliated with this study and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.

2. within 3 months prior to screening, complete or withdraw a clinical study, or are currently conducting a clinical study. Or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

3. have previously completed or withdrawn from this study.

4. 2h postprandial plasm glucose (2hPPG) ≥7.8 mmol / L（Test on -1 Day）.

5. have known allergies to compounds related to SY-008 capsules or multiple drug allergies, or have been treated with SGLT-1(sodium-glucose cotransporter-1) inhibitors in 1 year.

6. have significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (such as hemorrhoids, inflammation of GI tract, tumor, history of surgery, habitual bellyache or diarrheal disorders, other motility disorders), endocrine, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs or of constituting a risk when taking the study medication or interfering with the interpretation of data.

7. have a history of alcohol abuse or drug abuse.

8. show evidence or test positive on any of the following: hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibody (HCV), Treponema pallidum antibody (TP), HIV (HIV1 + 2) antibody.

9. have donated blood of 400 mL or more in the last 3 months or provided any blood donation within the last month from screening.

10. are subjects who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females; 1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits) or are subjects unwilling to stop alcohol consumption 24 hours prior to dosing until the completion of each inpatient study period.

11. consume more than 10 cigarettes per day or the equivalent, or are unable or unwilling to refrain from nicotine during the study.

12. intend to use over-the-counter or prescription medications within 14 days prior to dosing or during the study.

13. subjects not agree to use reliable contraceptive methods (hormones or barriers or abstinence) during the study period and at least 1 month after administration.

14. women were positive for blood pregnancy test within 24 hours prior to enrollment.

15. pregnant or lactating women.

16. in the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Suzhou Yabao Pharmaceutical R&D Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Feng Shao, Doctor

Role: PRINCIPAL_INVESTIGATOR

The Frist Affiliated Hospital Of Nanjing Madical University

Locations

The First Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China

Countries

China

Other Identifiers

SY008001

Identifier Type: -

Identifier Source: org_study_id